This article is more than 5 years old. Information may no longer be current.

Bevacizumab recall tops September news

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

September’s top ophthalmology-related news included FDA advancements for multiple drugs and a notable recall of bevacizumab.

Here are the top five articles on Healio.com/OSN in September:

AmEx recalls all lots of bevacizumab

All lots of bevacizumab 1.25 mg/0.05 mL 31-gauge injectable and bevacizumab 2.5 mg/0.1 mL Normject TB injectable from Pacifico National, doing business as AmEx Pharmacy, have been voluntarily recalled by the company. Read more.

VIDEO: J&J Vision launches Tecnis Synergy IOL, preloaded injectors

At the European Society of Cataract and Refractive Surgeons meeting, Tom Frinzi, worldwide president of surgical, Johnson & Johnson Vision, speaks about newly launched products: Tecnis Synergy, a continuous range of vision IOL for presbyopia, and two preloaded injectors, one disposable and one reusable. Read more.

FDA fast tracks potential treatment to prevent proliferative vitreoretinopathy

A phase 3 trial of ADX-2191 is planned for the fourth quarter and will compare recurrence rates of proliferative vitreoretinopathy-related retinal detachment in those treated with ADX-2191 compared with those treated with standard of care following surgical repair of retinal detachment. Read more.

FDA, European Medicines Agency advance abicipar pegol applications for wet AMD

The two filings are based on data from the CEDAR and SEQUOIA phase 3 trials, which assessed the efficacy and safety of abicipar compared with Lucentis (ranibizumab, Genentech). In both trials, abicipar showed similar efficacy in six or eight injections compared with 13 ranibizumab injections. Read more.

ProQR’s retinitis pigmentosa treatment receives fast track designation

QR-1123, designed to treat the underlying causes of vision loss associated with autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin gene, inhibits the formation of the mutated toxic version of the rhodopsin protein by binding the RHO mRNA. Read more.